[{"address1": "535 W 24th Street", "address2": "5th Floor", "city": "New York", "state": "NY", "zip": "10011", "country": "United States", "phone": "(855) 508-3568", "website": "https://www.neurogene.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.", "fullTimeEmployees": 91, "auditRisk": 5, "boardRisk": 7, "compensationRisk": 7, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 2, "previousClose": 31.07, "open": 31.3, "dayLow": 30.07, "dayHigh": 31.53, "regularMarketPreviousClose": 31.07, "regularMarketOpen": 31.3, "regularMarketDayLow": 30.07, "regularMarketDayHigh": 31.53, "forwardPE": -7.563415, "volume": 156137, "regularMarketVolume": 156137, "averageVolume": 105359, "averageVolume10days": 116580, "averageDailyVolume10Day": 116580, "bid": 30.35, "ask": 31.31, "bidSize": 100, "askSize": 100, "marketCap": 402519104, "fiftyTwoWeekLow": 12.2, "fiftyTwoWeekHigh": 53.0, "fiftyDayAverage": 34.3084, "twoHundredDayAverage": 26.348175, "currency": "USD", "enterpriseValue": 247393760, "floatShares": 6170700, "sharesOutstanding": 12980300, "sharesShort": 997788, "sharesShortPriorMonth": 988074, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0769, "heldPercentInsiders": 0.12777, "heldPercentInstitutions": 0.94047, "shortRatio": 13.4, "shortPercentOfFloat": 0.086, "impliedSharesOutstanding": 12980300, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": 8996000, "forwardEps": -4.1, "pegRatio": -0.3, "lastSplitFactor": "1:4", "lastSplitDate": 1702944000, "enterpriseToEbitda": -4.271, "52WeekChange": 0.9751593, "SandP52WeekChange": 0.26238096, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "NGNE", "underlyingSymbol": "NGNE", "shortName": "Neurogene Inc.", "longName": "Neurogene Inc.", "firstTradeDateEpochUtc": 1394202600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "51d6a4c2-efb6-34ae-b4ed-f6ab994594b8", "messageBoardId": "finmb_602062523", "gmtOffSetMilliseconds": -14400000, "currentPrice": 31.01, "targetHighPrice": 54.0, "targetLowPrice": 44.0, "targetMeanPrice": 48.5, "targetMedianPrice": 48.0, "recommendationMean": 1.3, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 4, "totalCash": 169532992, "totalCashPerShare": 13.061, "ebitda": -57923000, "totalDebt": 14408000, "quickRatio": 14.395, "currentRatio": 14.735, "debtToEquity": 8.437, "returnOnEquity": -0.30419, "operatingCashflow": -59517000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]